Logo

Rationale underlying the measurement of fractional exhaled nitric oxide in systemic sclerosis patients

1, 2, 3, 4, 5, 6, 7, 8, 9, 10

  1. Respiratory Unit, Luigi Sacco University Hospital Milan, Italy. rizzi.maurizio@asst-fbf-sacco.it
  2. L. Sacco Department of Biomedical Sciences, University of Milan, Italy.
  3. Respiratory Unit, Luigi Sacco University Hospital Milan, Italy.
  4. Respiratory Unit, Luigi Sacco University Hospital Milan, Italy.
  5. Respiratory Unit, Luigi Sacco University Hospital Milan, Italy.
  6. Respiratory Unit, Luigi Sacco University Hospital Milan, Italy.
  7. Respiratory Unit, Luigi Sacco University Hospital Milan, Italy.
  8. Rheumatology Unit, Department of Internal and Experimental Medicine, University of Messina, Italy.
  9. Rheumatology Unit, Luigi Sacco University Hospital, Milan, Italy.
  10. L. Sacco Department of Biomedical Sciences, University of Milan, Italy.

CER11810 Submission on line
2019 Vol.37, N°4 ,Suppl.119 - PI 0125, PF 0132
Reviews

Free to view (click on article PDF icon to read the article)

Rheumatology Article

 

Abstract

Systemic sclerosis (SSc) is an autoimmune disease characterised by tissue fibrosis leading to vascular injury. Nitric oxide (NO) has been implicated in the pathogenesis of autoimmune diseases. A deficiency in basal NO production by the constitutive endothelial isoform of nitric oxide synthase may promote vasoconstriction and vascular wall thickening. In January 2017, we searched the PubMed/Medline, Cochrane Library and Enbase/Medline databases for studies analysing physio-pathological correlations with lung fractional exhaled NO (FeNO) production. This review describes the rationale underlying possible applications of FeNO measurements in the management of SSc. Measuring NO levels at multiple expiratory flow rates makes it possible to distinguish airway NO production and distal airway/alveolar NO concentration (ANOC), and there is increasing evidence indicating that it may be useful in many non-respiratory conditions. FeNO levels are increased in SSc patients with fibrosing lung disease, whereas those with pulmonary hypertension have relatively low FeNO levels, thus suggesting that NO plays an important role in regulating pulmonary vascular resistance in SSc. However, a number of studies have shown increased ANOC in SSc patients without increased FeNO levels. The relationship between lung diffusing capacity for carbon monoxide and ANOC may be related to increased alveolar membrane thickness impeding NO diffusion or alveolar inflammation in SSc lung disease. The findings concerning the usefulness of FeNO measurements in SSc patients are discordant, but the available papers suggest that ANOC is a more accurate indicator of progressive lung dysfunction and an increase in ANOC could assess the extent of interstitial lung disease non-invasively.

PMID: 30873947 [PubMed]

Received: 10/10/2018 - Accepted : 07/01/2019 - In Press: 27/02/2019 - Published: 03/10/2019